

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature	/Marcela M Cordero Garcia/	Date Considered	07/04/2008
-----------------------	----------------------------	--------------------	------------

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	11/391,027
				Filing Date	March 28, 2006
				First Named Inventor	Bruce F. Molino
				Group Art Unit	1654
				Examiner Name	Ronald Neibauer
				Attorney Docket Number	2809/1680
Sheet	2	of	2		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/MMCG/	4	Pacshuyse et al., "Potent and Selective Inhibition of Hepatitis C Virus Replication by the Non-Immunosuppressive Cyclosporin Analogue DEBIO-025," <i>Antiviral Research</i> 65(3):A41 (2005)	
/MMCG/	5	Nakagawa et al., "Specific Inhibition of Hepatitis C Virus Replication by Cyclosporin A," <i>Biochem. Biophys. Res. Commun.</i> 313:42-47 (2004)	
/MMCG/	6	Inoue et al., "Combined Interferon α 2b and Cyclosporin A in the Treatment of Chronic Hepatitis C: Controlled Trial," <i>J. Gastroenterol.</i> 38:567-572 (2003)	
/MMCG/	7	Bandera et al., "Immunomodulants in HIV Infection," <i>Expert Opin. Ther. Patents</i> 15(9):1115-1131 (2005)	
/MMCG/	8	Bartz et al., "Inhibition of Human Immunodeficiency Virus Replication by Non-Immunosuppressive Analogs of Cyclosporin A," <i>Proc. Natl. Acad. Sci. USA</i> 92:5381-5385 (1995)	
/MMCG/	9	Prelog et al., "Treatment of Psoriatic Arthritis with Cyclosporin A," <i>Acta Dermatovenerologica, Alpina, Pannonica et Adriatica</i> , 9(3):1-5 (2000)	
/MMCG/	10	The Merck Manual online version, www.merck.com/mmhe , Common Cold, pp. 1-3 (October 27, 2004)	
/MMCG/	11	The Merck Manual online version, www.merck.com/mmhe , Viral Infections, pp. 1-4 (March 20, 2005)	
/MMCG/	12	Rosenwirth et al., "Debio-025, A Novel Non-Immunosuppressive Cyclosporine Analog with Potent Anti-Human Immunodeficiency Virus Type 1 Activity: Pharmacological Properties and Mode of Action," <i>Antiviral Research</i> , 64(3):42-43 (2005)	
/MMCG/	13	DEB 025, ADIS Database, pp. 1-2 (October 12, 2005)	

Examiner Signature	/Marcela M Cordero Garcia/	Date Considered	07/04/2008
--------------------	----------------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.